



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH



European Network of Centres for  
Pharmacoepidemiology and  
Pharmacovigilance

EMA/95098/2010 Rev.6

## The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)

### Guide on Methodological Standards in Pharmacoepidemiology (Revision 6)

#### **ENCePP Guide, Revision 6 - Authorship**

##### ***Editors***

Alexandra Pacurariu, Xavier Kurz and the ENCePP Working Group 'Research Standards and Guidances'

##### ***Design and layout***

Dagmar Vogl

##### ***Main authors***

- 1. Introduction:** Xavier Kurz
- 2. Formulating the research question:** Yola Moride, Massoud Toussi
- 3. Development of the study protocol:** Annie Fourrier-Réglat
- 4. Approaches to data collection**
  - 4.1. Primary data collection:** Susana Perez-Gutthann, Hubert Leufkens
    - 4.1.1. Surveys:** Massoud Toussi
    - 4.1.2. Randomised clinical trials:** Susana Perez-Gutthann, Hubert Leufkens
  - 4.2. Secondary data collection:** Susana Perez-Gutthann

---

30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom

**Telephone** +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555

**Send a question via our website** [www.ema.europa.eu/contact](http://www.ema.europa.eu/contact)

An agency of the European Union



**4.3. Patient registries:** Xavier Kurz

**4.4. Spontaneous report databases:** Niklas Norèn, Jim Slattery

**4.5. Social media and electronic devices:** Annie Fourrier-Réglat, Yvonne Lis, Daniel Morales, Massoud Toussi

**4.6. Research networks:** Miriam Sturkenboom

## **5. Study design and methods**

**5.1. Definition and validation of drug exposure, outcomes and covariates:** Alejandro Arana, Gillian Hall, Jesper Hallas, Rachael Williams

**5.2. Bias and confounding:** Olaf Klungel, Jesper Hallas, Mirko Di Martino, Ursula Kirchmayer, Alejandro Arana, Alexandra Pacurariu

**5.3. Methods to handle bias and confounding:** Rolf Groenwold, Jesper Hallas, Olaf Klungel,

**5.4. Effect measure modification and interaction:** Olaf Klungel, Federica Pisa

**5.5. Ecological analyses and case-population studies:** Ursula Kirchmayer

**5.6. Pragmatic and large simple trials:** Olaf Klungel, Yvonne Lis, Tjeerd van Staa

**5.7. Systematic review and meta-analysis:** Gillian Hall, Victor Kiri, Nawab Qizilbash

**5.8. Signal detection methodology and application:** Niklas Norèn, Jim Slattery

**6. The statistical analysis plan:** Jim Slattery, Alejandro Arana

**7. Quality management:** Milena Jadrijević-Mladar Takač

**8. Dissemination and reporting:** Kevin Blake, Susana Perez-Gutthann

## **9. Data protection and ethical aspects**

**9.1. Patient and data protection:** Xavier Kurz, Kevin Blake

**9.2. Scientific integrity and ethical conduct:** Xavier Kurz, Kevin Blake

## **10. Specific topics**

**10.1. Comparative effectiveness research:** Annie Fourrier-Réglat, Olaf Klungel, Federica Pisa

**10.2. Vaccine safety and effectiveness:** Phillip Bryan, Alfonso Carvajal, Stephen Evans, Kevin Blake, Alain Moren, Xavier Kurz

**10.3. Design and analysis of pharmacogenetic studies:** Olaf Klungel, Bruce Carleton (in collaboration with the ISPE SIG "Molecular Epidemiology, Biomarkers and Pharmacogenetics")

**Annex 1** Nawab Qizilbash, Jim Slattery and Kevin Blake

## ***Acknowledgements***

Peer review of one or several chapters was received from:

Amalia Issa

Ana Marta Anes

Ann Daly

Annalisa Rubino

Brian Strom

Camilla Stephens

Consuelo Pedros

David Martin

Elisabetta Poluzzi

Frank DeStefano

Geoff Liu

Gillian Bartlet

Gonzalo Calvo

Gunilla Sjolin-Forsberg

Hervé Le Louet

Ivana Silva

Jan Bonhoeffer

John Parkinson

Kenneth J. Rothman

Lina Titievski

Marina Davoli

Mark de Groot

Martin Daumer

Michael Theodorakis

Munir Pirmohamed

Nada Božina

Nancy Dreyer

Paddy Farrington

Patrick Zuber

Peter Arlett

Robert Vander Stichele

Samy Suissa

Sarah McFarlane

Sebastian Botzenhardt

Sebastian Schneeweiss

Stefanie Prilla

Teresa Herdeiro

Ulf Bergman  
Vera Ehrenstein  
Wei Zhou  
Xavier Fournie